Search Results

South Korea's Daewoong Pharmaceutical Partners with Promedius to Promote AI Osteoporosis Screening Solution Using Chest X-rays

Daewoong Pharmaceutical announced on August 27 that it has signed a sales, distribution, and joint promotion agreement with Promedius, a medical imaging AI company, to promote Osteo Signal, an AI-based osteoporosis risk screening solution using chest X-rays, in South Korea. This partnership also marks Daewoong Pharmaceutical's expansion from its existing osteoporosis treatment business into the AI-assisted diagnostics field. Under the agreement, Daewoong Pharmaceutical will leverage its business network covering medical institutions across South Korea, along with its sales and marketing capabilities, to bring the solution into more clinical settings. Promedius will provide medical imaging AI technical support to assist in its deployment in real-world medical environments.

2026-08-27

Huzhou, Zhejiang Launches Phase I "Drug-Device Combination" Clinical Trial for the Province's First BNCT System

Recently, the Boron Neutron Tumor Treatment Center at Huzhou Hospital Affiliated to Zhejiang University School of Medicine has drawn attention with the introduction of the province's first Boron Neutron Capture Therapy (BNCT) system. Previously, the system had already initiated a Phase I BNCT drug-device combination clinical trial. According to the system developer, Huapeng Neutron Technology (Hangzhou) Co., Ltd., BNCT is a radiotherapy technique combining drugs and devices, with its core lying in the coordinated use of boron-containing drugs and neutron irradiation. After entering the human body, the boron-containing drug can be absorbed by tumor cells; subsequent neutron beam irradiation triggers a localized reaction to achieve targeted radiotherapy against tumor cells. Unlike conventional radiotherapy, which typically employs fractionated irradiation over a longer treatment course, BNCT emphasizes selective targeting of tumor cells, aiming to reduce damage to surrounding healthy tissues and lower radiotherapy-related side effects such as hair loss and immunosuppression.

2026-08-27

Moffitt Cancer Center in the U.S. Launches $600 Million Radiopharmaceutical Program

Moffitt Cancer Center in Tampa, Florida, recently announced the launch of a new radiopharmaceutical program, planning to accelerate radiopharmaceutical research, development, and clinical translation through a total infrastructure investment of $600 million. The program will be advanced at the Speros campus of Moffitt Cancer Center in Pasco County, Florida. The campus spans 775 acres, and the related investment will support the development of radiopharmaceutical research and development capabilities, including the construction of new radiochemistry laboratories within the Moffitt Discovery and Innovation Center, which opens this fall. The innovation center has a building area of approximately 255,000 square feet. The program funding will also support the planned comprehensive theranostics center...

2026-08-27

South Korea's KSTAR to Conduct Long-Pulse Fusion Research in Tungsten Environment with European Institutions

The Korea Institute of Fusion Energy (KFE) announced on August 27 that it has signed implementation agreements with multiple fusion research institutions in France, Italy, Germany, and Finland to conduct joint research on long-duration plasma operation in a tungsten environment using the Korea Superconducting Tokamak Advanced Research (KSTAR) device. Partner institutions include the French Alternative Energies and Atomic Energy Commission (CEA), the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), the Max Planck Institute for Plasma Physics (IPP) in Germany, and the VTT Technical Research Centre of Finland (VTT). The institutions will focus on key technologies required for long-pulse operation of future fusion reactors...

2026-08-27

France's n-Floating Floating Nuclear Power Project Receives Nearly One Million Euros in Funding

newcleo announced on August 26 that a consortium led by the company has been selected for a call for projects managed by Bpifrance, the French public investment bank, supporting the decarbonization of France's maritime sector. The consortium will advance research on a floating nuclear power solution called n-Floating, with the project receiving nearly one million euros in funding and an expected duration of approximately 18 months. The n-Floating project aims to validate the relevance and technical feasibility of a new floating nuclear power solution. Under the proposed concept, a non-self-propelled floating unit would carry multiple LFR-AS-200 reactors, each with an electrical output of 200 megawatts. LFR-AS-200 is one of the lead-cooled fast reactor technology lines developed by newcleo.

2026-08-27

Japan's JT-60SA Experimental Team Advances Preparations for Next Operation Phase

Preparations for the next phase of JT-60SA experimental activities are underway. The technical team is carrying out integrated commissioning as planned, while the experimental team is simultaneously refining related tools and software to enhance scientific output capabilities for the next operation phase. During a training course organized by QST, EUROfusion participants are learning how to configure discharge settings using the Human-Machine Interface (HMI) in preparation for the next JT-60SA campaign. Image credit: QST. The Third JT-60SA Experimental Team Workshop was held from July 27 to 31, 2026, at the Naka Institute of the National Institutes for Quantum Science and Technology (QST) in Japan. Approximately 50 experts attended, including 20 representatives from Europe...

2026-08-26

UK's InHealth Deploys Europe's First Mobile Biograph Trinion PET/CT System

InHealth, a UK independent diagnostic service provider, has recently completed the first patient scan using Europe's first mobile Biograph Trinion PET/CT system. The system, supplied by Siemens Healthineers, is now in clinical use at Wrexham Maelor Hospital in northeast Wales to support cancer-related molecular imaging examinations. PET/CT is an important imaging technology in oncology diagnosis and treatment, applicable to the diagnosis, staging, treatment planning, and therapy response monitoring of various cancer types. Deploying the Biograph Trinion PET/CT system on a mobile platform means that advanced molecular imaging services can be delivered into clinical settings with greater flexibility, helping to improve patient access to...

2026-08-26

Why Swedish Nuclear Power Plants Are Less Affected by European Heatwaves

This summer, persistent high temperatures across much of Europe forced some nuclear power plants to reduce output or even temporarily shut down due to rising cooling water temperatures and falling river levels. In comparison, Sweden's Vattenfall-operated nuclear plants at Forsmark and Ringhals were less affected, mainly because both facilities are located in coastal areas and use seawater for cooling. Many nuclear plants in continental Europe rely on river water as their cooling source. During heatwaves, river levels and water temperatures can change rapidly, easily impacting cooling efficiency. Anna Collin, Communications Officer at Ringhals, stated that Swedish nuclear plants use seawater cooling, which differs in operating conditions from many...

2026-08-26

Phase II of China Spallation Neutron Source in Dongguan expected to be completed by 2029

On August 26, a media delegation from the Guangdong-Hong Kong-Macao Greater Bay Area visited the China Spallation Neutron Source (CSNS) in Dongguan to learn about the operation of this major scientific facility and the progress of its Phase II project. The CSNS is China's first and the world's fourth pulsed spallation neutron source, often referred to as a "super microscope" for exploring the microscopic world. Since its opening in 2018, the facility has been operating in areas including basic research, research addressing major national needs, industrial innovation, and the integration of Hong Kong and Macao in science and technology innovation, and has become one of the key scientific research platforms in the Greater Bay Area. Tong Xin, Deputy Director of the Spallation Neutron Source Science Center, stated that the Phase II project of the CSNS is currently under construction, with a construction period from January 2024 to October 2029...

2026-08-26

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

IAEA Study: Five-Star Rating System Can Improve CT Imaging Safety and Reduce Unnecessary Radiation Exposure

A new study led by the International Atomic Energy Agency (IAEA) in collaboration with Massachusetts General Hospital and Harvard Medical School in Boston, USA, shows that a five-star rating system can help hospitals optimize image quality, reduce radiation dose, and decrease unnecessary patient radiation exposure in computed tomography (CT) examinations. The study has been published in the European Journal of Radiology. CT imaging uses X-rays to obtain detailed images of internal body structures and is an important tool in diagnosing a wide range of diseases. The study notes that CT image quality is closely related to radiation dose—higher doses typically reduce image noise and improve clarity, but do not always yield additional diagnostic value. How to minimize radiation exposure while ensuring diagnostic accuracy is key to optimizing CT examination protocols.

2026-08-26

Singapore team develops deuterated silicon nitride waveguides for wafer-scale broadband light generation

A research team from the Singapore University of Technology and Design and the Institute of Microelectronics at the Agency for Science, Technology and Research (A*STAR) in Singapore has recently developed a low-loss deuterated silicon nitride waveguide capable of on-chip broadband light generation. By replacing hydrogen with its heavier isotope deuterium, the team fabricated silicon nitride waveguides at low temperatures, demonstrating potential for integration with CMOS-compatible semiconductor processes and wafer-scale mass production. The related paper, "Octave-spanning supercontinuum generation in wafer-scale low-loss deuterated silicon nitride waveguides," was published in *Optics Letters*. The study shows that this chip-scale waveguide can broaden infrared laser pulses to cover a spectral range from visible red light to deep infrared. Traditionally, silicon nitride thin films are grown from silane gas, and residual silicon-hydrogen bonds in the material absorb light in the telecommunications band, requiring high-temperature annealing that is incompatible with integrated electronic circuits.

2026-08-26

Molecular Partners Advances DLL3 Radiopharmaceutical MP0712 to Higher Dose Cohort

Swiss clinical-stage biotechnology company Molecular Partners AG recently announced its business progress and financial results for the first half of 2026. The company stated that its DLL3-targeting radioactive DARPin therapy MP0712 has advanced to the second therapeutic dose level in a U.S. multicenter Phase 1/2a clinical study, and patient enrollment for the new dose cohort is currently underway. MP0712 is a radiopharmaceutical targeting the tumor-associated antigen DLL3, carrying a therapeutic alpha-emitting radionuclide lead-212 (Pb-212) payload, co-developed by Molecular Partners and Orano Med, primarily for small cell lung cancer and other neuroendocrine tumors. According to the company's disclosure, the first dose cohort of MP0712...

2026-08-26

Korea's Shin-Kori Unit 1 Reaches Full Power After Scheduled Maintenance

Korea Hydro & Nuclear Power (KHNP) announced that Shin-Kori Unit 1 reached 100% rated power at approximately 3:07 a.m. on the 26th. The unit is a 1,400 MW-class pressurized water reactor. Shin-Kori Unit 1 began its sixth scheduled preventive maintenance on July 2 and resumed power generation on July 23. During the maintenance period, the unit underwent statutory inspections as required by Korea's Nuclear Safety Act. Shin-Kori nuclear power plant stated that this maintenance included nuclear fuel replacement, as well as maintenance and inspection of major equipment and facilities to enhance the safety and reliability of the power generation facility....

2026-08-26

Russia and Algeria Advance Cooperation in Peaceful Uses of Nuclear Energy

August 22 news, Russian Ambassador to Algeria Alexey Solomatin said in an interview that Russia and Algeria are advancing cooperation in the field of peaceful uses of nuclear energy, with direct working contacts established between the relevant agencies of the two countries. Solomatin stated that cooperation between the two countries in this field is expanding. The basis for bilateral cooperation is the Intergovernmental Agreement on Cooperation in the Peaceful Uses of Nuclear Energy signed in 2014. In addition, Russia and Algeria signed the Roadmap for Cooperation in the Peaceful Uses of Nuclear Energy during the 2024 International Atomic Energy Expo (Atomexpo), outlining the main directions of bilateral cooperation. He noted that the practical implementation of the agreements will begin in 2...

2026-08-25